-
21.发明公开METHOD FOR DIFFERENTIATION INDUCTION OF MYOCARDIAL CELL FROM PLURIPOTENT STEM CELL 审中-公开Methode zur Induktion der Differenzierung von Myokardzellen aus pluripotenten Stammzellen
公开(公告)号：EP2014766A1
公开(公告)日：2009-01-14
申请号：EP07742677.3
申请日：2007-04-27
CPC分类号： C12N5/0657 , C12N2501/415 , C12N2506/02
摘要： The present invention provides a method for inducing differentiation of cardiomyocytes efficiently and selectively from stem cells.
A method for inducing differentiation of cardiomyocytes from pluripotent stem cells, which comprises: (i) culturing the pluripotent stem cells in a culture medium containing no substance that promotes activation of the canonical Wnt signaling pathway during the time period between initiation of differentiation induction and 24 hours before the period of elevated canonical Wnt gene expression; and then (ii) culturing the pluripotent stem cells in a culture medium containing a substance that promotes activation of the canonical Wnt signaling pathway during a time period of 24 to 96 hours, starting from 24 to 0 hours before the period of elevated canonical Wnt gene expression.摘要翻译： 本发明提供了从干细胞中有效且选择性地诱导心肌细胞分化的方法。 一种从多能干细胞诱导心肌细胞分化的方法，包括：（i）在不分泌诱导开始和分化诱导期间的时间段内不含促进标准Wnt信号通路活化的培养基中培养多能干细胞 在正常Wnt基因表达升高之前的几个小时; 然后（ii）在培养基中培养多能干细胞，该培养基含有促进典型Wnt信号通路活化的物质的培养基，时间为24至96小时，从升高的典型Wnt基因的时期开始至24小时 表达。
-
22.发明公开
公开(公告)号：EP1964566A4
公开(公告)日：2009-01-07
申请号：EP06835070
申请日：2006-12-21
申请人： ASUBIO PHARMA CO LTD
发明人： OKITSU MITSUHITO , OGAT ATSUTO , TANI YOSHIHIRO
CPC分类号： A61K9/1617 , A61K9/145 , A61K9/2013 , A61K9/4858 , A61K31/519
摘要： It is intended to provide a method for significantly improving the bioavailability of orally administered sapropterin hydrochloride which is used as a therapeutic agent for BH4 responsive hyperphenylalaninemia and a preparation for oral administration or a preparation for oral intake with improved bioavailability. It is a preparation in which the bioavailability of sapropterin hydrochloride has been improved characterized by containing sapropterin hydrochloride and an absorption promoter comprising an organic carboxylic acid having a plurality of carboxyl groups in its molecule, wherein the organic carboxylic acid containing a plurality of carboxyl groups in its molecule is selected from tartaric acid, citric acid, malic acid, or an optically active substance, a racemic compound, an anhydride or a hydrate thereof or a mixture thereof and the addition amount thereof is 0.1 to 100 times the weight of sapropterin hydrochloride.
-
公开(公告)号：EP1076097B1
公开(公告)日：2008-11-12
申请号：EP00906696.0
申请日：2000-03-03
IPC分类号： C12P21/02 , C12N15/62 , C12N15/63 , C07K14/58 , C07K14/585 , C07K14/605
CPC分类号： C07K14/585 , C07K14/58 , C07K14/605 , C07K2319/50 , C07K2319/75 , C12N15/62 , C12N15/63
-
24.发明公开THERAPEUTIC AGENT FOR SKIN OR SKIN REPAIR-PROMOTING AGENT COMPRISING GHRELIN, DERIVATIVE THEREOF OR SUBSTANCE CAPABLE OF ACTING ON GHS-R1a AS ACTIVE INGREDIENT 审中-公开治疗剂的皮肤用或皮肤修复PROMOTIONAL AGENTS生长素释放肽，其衍生物或ON GHS-R 1a中工作物质可; 为活动
公开(公告)号：EP1967208A1
公开(公告)日：2008-09-10
申请号：EP06833072.9
申请日：2006-11-21
申请人： The University of Miyazaki , Japan as represented by president of National Cardiovascular Center , Asubio Pharma Co., Ltd.
摘要： The present invention provides a novel therapeutic agent for skin injuries and a skin regeneration accelerator. The therapeutic agent for skin injuries and the skin regeneration accelerator containing a substance acting on a growth hormone secretagogue receptor or a pharmaceutically acceptable salt thereof as an active ingredient.
摘要翻译： 本发明提供了用于皮肤损伤和皮肤再生促进剂的新的治疗剂。 用于皮肤损伤治疗剂和含有作用于生长激素促分泌素受体或其药学上可接受的盐在其作为活性成分的物质的皮肤再生促进剂。
-
公开(公告)号：EP1693451A4
公开(公告)日：2007-11-07
申请号：EP04818986
申请日：2004-11-19
申请人： ASUBIO PHARMA CO LTD
IPC分类号： C12N15/09 , A61K31/7088 , A61K35/12 , A61K35/34 , A61K35/76 , A61K48/00 , A61P9/00 , A61P9/04 , A61P9/10 , C07K14/47 , C12N5/077 , C12N5/10 , C12N9/12
CPC分类号： C12N5/0657 , A61K31/7088 , A61K35/12 , A61K48/00 , C07K14/4738 , C12N9/1205 , C12N2510/00
摘要： The growth of myocardial cells is induced by expressing cycline and CDK in the myocardial cells and regulating the function or action of a Cip/Kip protein, or by inhibiting the production of a Cip/Kip protein. Among the Cip/Kip family proteins, it is preferable to regulate the function of p27Kip1 or inhibiting the production thereof. As a recombinant vector to be used therefor, it is intended to provide a vector having: (1) a cyclin gene; (2) a cyclin-dependent kinase gene and (3) one or more members selected from the group consisting of a gene encoding a factor inhibiting the function or action of a Cip/Kip protein and nucleic acid sequences inhibiting the production of Cip/Kip family proteins.
-
公开(公告)号：EP1466610A4
公开(公告)日：2007-03-21
申请号：EP02783628
申请日：2002-11-26
IPC分类号： A61K38/00 , A61K9/00 , A61K38/22 , A61K38/26 , A61K38/28 , A61K47/02 , A61K47/46 , A61K9/14 , A61K47/12 , A61K47/34 , A61K47/36 , A61K47/38
CPC分类号： A61K9/0043 , A61K38/2278 , A61K38/26 , A61K38/28 , A61K47/02 , A61K47/46
摘要： A pharmaceutical composition for nasal administration exhibits an improved bioavailability of a biologically active polypeptide, the active ingredient of the pharmaceutical composition. Specifically, the composition is prepared by uniformly dispersing and embedding a biologically active acidic polypeptide having an isoelectric point of 7 or lower on the surfaces of a polyvalent metal compound carrier with the help of an additive capable of dispersing and embedding the polypeptide on the surfaces of the carrier. The polyvalent metal compound carrier is a metal compound with a valent of 2 or higher that is either insoluble or little soluble in water, examples being aluminum compounds, calcium compounds, magnesium compounds, silicone compounds, iron compounds, and zinc compounds.
-
27.发明授权THERAPEUTIC TREATMENT OF EOSINOPHILIA USING CHYMASE INHIBITORS AS THE ACTIVE INGREDIENT 有权按用途分的抑制剂作为活性成分糜酶嗜酸细胞治疗
公开(公告)号：EP1174151B1
公开(公告)日：2007-01-24
申请号：EP01906225.6
申请日：2001-02-22
IPC分类号： A61K45/00 , A61K31/517 , A61K31/536 , A61P43/00 , A61P37/08 , A61P11/06 , A61P27/16 , A61P27/14 , A61P17/04 , C07D239/96
CPC分类号： C07D239/96 , A61K31/00 , A61K31/517 , A61K31/536
摘要： Preventive or therapeutic drugs, which inhibit the progression of eosinophilia-related diseases while preventing the progression of various complications, and are so safe by virtue of their being free from adverse effects as to bring about enhancement in the quality of daily life of a patient. Specifically, preventive or therapeutic drugs for eosinophilia-related diseases containing chymase inhibitors as the active ingredient, wherein the chymase inhibitors are quinazoline derivatives of the general formula (I) or pharmacologically acceptable salts thereof: (I)
-
28.发明授权
公开(公告)号：EP1192950B1
公开(公告)日：2006-07-26
申请号：EP01906226.4
申请日：2001-02-22
IPC分类号： A61K45/00 , A61K31/517 , A61K31/536 , A61P43/00 , A61P17/00 , A61P17/04 , C07D239/96 , C07D401/12 , C07D403/12
CPC分类号： C07D239/96 , A61K31/00 , A61K31/517
摘要： Preventive or therapeutic drugs for dermatitises accompanied with dimorphic inflammatory reactions and those caused by repeated exposure to antigens, which inhibit the progression of such dermatitises and are so safe by virtue of their being free from adverse effects as to bring about enhancement in the quality of daily life of a patient. Specifically, remedies for the above dermatitisescontaining chymase inhibitors as the active ingredient, wherein the chymase inhibitors are quinazoline derivatives of the general formula (I) or (II) or pharmacologically acceptable salts thereof.
-
29.发明公开
公开(公告)号：EP1459758A4
公开(公告)日：2006-02-22
申请号：EP02793466
申请日：2002-12-27
发明人： MIURA KENJU , HARUYAMA MUNETADA , KODAMA SHIHO
CPC分类号： A61K38/18 , A61K38/1709 , A61K38/202 , A61K2300/00
摘要： It is intended to provide agents promoting the proliferation and/or differentiation of hematopoietic stem cells and/or hematopoietic precursor cells which are useful as remedies for diseases induced by the insufficient proliferation and/or differentiation of hematopoietic stem cells and/or hematopoietic precursor cells, in particular, diseases associated with a diffuse decrease in hematopoietic cells and/or hematopoietic hypofunction. The above problem is solved by providing agents for promoting the proliferation and/or differentiation of hematopoietic stem cells and/or hematopoietic precursor cells which contain as the active ingredient cofilin.
-
公开(公告)号：EP1008346B1
公开(公告)日：2006-02-15
申请号：EP99909284.4
申请日：1999-03-19
IPC分类号： A61K31/12 , A61K31/165 , A61K31/19 , A61K31/245 , A61K31/335 , A61K31/36 , A61K31/40 , A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/54 , A61K31/55 , C07C66/00 , C07C235/78 , C07D207/04 , C07D211/16 , C07D211/22 , C07D211/32 , C07D211/42 , C07D211/46
CPC分类号： C07D319/18 , A61K31/00 , A61K31/12 , A61K31/122 , A61K31/165 , A61K31/19 , A61K31/245 , A61K31/335 , A61K31/36 , A61K31/40 , A61K31/44 , A61K31/445 , A61K31/495 , A61K31/535 , A61K31/54 , A61K31/55 , C07C50/28 , C07C235/78 , C07C2601/18 , C07D207/08 , C07D207/10 , C07D211/22 , C07D211/60 , C07D213/74 , C07D215/08 , C07D223/10 , C07D295/185 , C07D317/66 , A61K2300/00
摘要： NF-λB inhibitors containing as the active ingredient benzoquinone derivatives represented by general formula (I), hydroquinone compounds thereof or salts of the same, wherein R1, R2 and R3 independently represent each H, C1-5 alkyl or C1-5 alkoxy; R4 represents H, hydroxy-methyl, alkyl or optionally esterified or amidated carboxy; Z is represented by formula (A); and n is from 0 to 6.
-
-
-
-
-
-
-
-
-
搜索结果
99 条记录 (耗时 0.017 秒)
